GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative ...

SandboxAQ today announced it has expanded its relationship with Deloitte to offer SandboxAQ's AI LQM simulation products and solutions along with Deloitte's services capabilities to organizations ...

The graph below depicts this surprise history: The increasing life expectancy of the U.S. population and biopharma drug development growth opportunities have promoted lab real estate market ...

Healthpeak Properties, Inc. DOC is slated to report its fourth-quarter 2024 results on Feb. 3, after market close. While the quarterly results are expected to reflect year-over-year growth in revenues ...

In the past few years, there has been extensive usage of knowledge graphs (KG) that connect concepts ... is a senior consultant at MP Advisors, a biopharma-only strategy and financial advisory ...

Tools like knowledge graphs have been pivotal in uncovering ... She advises clients on a wide range of assignments in the sector (from biopharma to pharma service providers), including the ...

representing a compelling opportunity for Accord BioPharma to broaden patient access to biologics and build scale in immunology, a high-demand therapeutic area. "Our U.S. portfolio of biosimilars ...

Wolfe Research initiated coverage of Zenas BioPharma (ZBIO) with an Outperform rating and $19 price target After its IPO in September 2024, the stock traded down significantly along with many ...

Wolfe Research initiated coverage of Zenas BioPharma (ZBIO) with an Outperform rating. Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and ...